JP2007536211A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007536211A5 JP2007536211A5 JP2006539398A JP2006539398A JP2007536211A5 JP 2007536211 A5 JP2007536211 A5 JP 2007536211A5 JP 2006539398 A JP2006539398 A JP 2006539398A JP 2006539398 A JP2006539398 A JP 2006539398A JP 2007536211 A5 JP2007536211 A5 JP 2007536211A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- factor
- immunoglobulin
- group
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000018102 proteins Nutrition 0.000 claims 30
- 102000004169 proteins and genes Human genes 0.000 claims 30
- 108090000623 proteins and genes Proteins 0.000 claims 30
- 102000018358 Immunoglobulins Human genes 0.000 claims 26
- 108060003951 Immunoglobulins Proteins 0.000 claims 26
- 229920000642 polymer Polymers 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 230000000975 bioactive Effects 0.000 claims 9
- 210000004027 cells Anatomy 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 108090001123 antibodies Proteins 0.000 claims 6
- 102000004965 antibodies Human genes 0.000 claims 6
- 239000003102 growth factor Substances 0.000 claims 6
- 101700033006 EGF Proteins 0.000 claims 4
- 102100010813 EGF Human genes 0.000 claims 4
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 229940116977 Epidermal Growth Factor Drugs 0.000 claims 4
- 102000002265 Human Growth Hormone Human genes 0.000 claims 4
- 108010000521 Human Growth Hormone Proteins 0.000 claims 4
- 239000000854 Human Growth Hormone Substances 0.000 claims 4
- 210000002540 Macrophages Anatomy 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N Succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims 4
- 125000003172 aldehyde group Chemical group 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000038129 antigens Human genes 0.000 claims 4
- 108091007172 antigens Proteins 0.000 claims 4
- 229940019336 antithrombotic Enzymes Drugs 0.000 claims 4
- 230000027455 binding Effects 0.000 claims 4
- 229960000182 blood factors Drugs 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 claims 4
- 229920001519 homopolymer Polymers 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 102000002467 interleukin receptors Human genes 0.000 claims 4
- 108010093036 interleukin receptors Proteins 0.000 claims 4
- 230000002188 osteogenic Effects 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- -1 succinimidyl carboxymethyl Chemical group 0.000 claims 4
- 229960005486 vaccines Drugs 0.000 claims 4
- ZJIFDEVVTPEXDL-UHFFFAOYSA-M (2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound [O-]C(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-M 0.000 claims 2
- AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical group CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 claims 2
- WZHKXNSOCOQYQX-FUAFALNISA-N (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 claims 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 1-butanal Chemical group CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims 2
- XRZWVSXEDRYQGC-UHFFFAOYSA-N 4-cyclohexylpyrrolidin-1-ium-2-carboxylate Chemical compound C1NC(C(=O)O)CC1C1CCCCC1 XRZWVSXEDRYQGC-UHFFFAOYSA-N 0.000 claims 2
- 102100001249 ALB Human genes 0.000 claims 2
- 101710027066 ALB Proteins 0.000 claims 2
- 102100007877 APOE Human genes 0.000 claims 2
- 101700025839 APOE Proteins 0.000 claims 2
- 102000009840 Angiopoietins Human genes 0.000 claims 2
- 108010009906 Angiopoietins Proteins 0.000 claims 2
- 102400000068 Angiostatin Human genes 0.000 claims 2
- 108010079709 Angiostatins Proteins 0.000 claims 2
- 108010064733 Angiotensins Proteins 0.000 claims 2
- 102000015427 Angiotensins Human genes 0.000 claims 2
- 102000025380 C-Reactive Protein Human genes 0.000 claims 2
- 108010074051 C-Reactive Protein Proteins 0.000 claims 2
- 102100013472 CCK Human genes 0.000 claims 2
- 102400000113 Calcitonin Human genes 0.000 claims 2
- 108060001064 Calcitonin Proteins 0.000 claims 2
- 229960004015 Calcitonin Drugs 0.000 claims 2
- NSQLIUXCMFBZME-MPVJKSABSA-N Carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims 2
- 210000000845 Cartilage Anatomy 0.000 claims 2
- 229920002101 Chitin Polymers 0.000 claims 2
- 108010048926 Cholecystokinin Proteins 0.000 claims 2
- 229940107137 Cholecystokinin Drugs 0.000 claims 2
- 229940047120 Colony stimulating factors Drugs 0.000 claims 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 2
- 210000002808 Connective Tissue Anatomy 0.000 claims 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 2
- 101700057276 ENPP2 Proteins 0.000 claims 2
- 102100016621 ENPP2 Human genes 0.000 claims 2
- JYSJVJJVLNYRKL-QPHHPWFVSA-N Elcatonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)C1CCCCCC(=O)OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 JYSJVJJVLNYRKL-QPHHPWFVSA-N 0.000 claims 2
- 229960000756 Elcatonin Drugs 0.000 claims 2
- 102100009906 F7 Human genes 0.000 claims 2
- 229950003499 FIBRIN Drugs 0.000 claims 2
- 230000035693 Fab Effects 0.000 claims 2
- 108010023321 Factor VII Proteins 0.000 claims 2
- 108010073385 Fibrin Proteins 0.000 claims 2
- 102000009123 Fibrin Human genes 0.000 claims 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 2
- 229940028334 Follicle Stimulating Hormone Drugs 0.000 claims 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 2
- 108091006011 G proteins Proteins 0.000 claims 2
- 101710044881 GHRH Proteins 0.000 claims 2
- 102100003313 GHRL Human genes 0.000 claims 2
- 101700010630 GHRL Proteins 0.000 claims 2
- 108091000058 GTP-Binding Proteins Proteins 0.000 claims 2
- 102000030007 GTP-Binding Proteins Human genes 0.000 claims 2
- 102000004862 Gastrin releasing peptide Human genes 0.000 claims 2
- 108090001053 Gastrin releasing peptide Proteins 0.000 claims 2
- PUBCCFNQJQKCNC-XKNFJVFFSA-N Gastrin-ReleasingPeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 claims 2
- 108060003199 Glucagon Proteins 0.000 claims 2
- 229960004666 Glucagon Drugs 0.000 claims 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 claims 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 2
- 102000003886 Glycoproteins Human genes 0.000 claims 2
- 108090000288 Glycoproteins Proteins 0.000 claims 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N Gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 2
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims 2
- 102000038586 Growth Hormone-Releasing Hormone Human genes 0.000 claims 2
- 101700042506 HIRUD Proteins 0.000 claims 2
- 102000001554 Hemoglobins Human genes 0.000 claims 2
- 108010054147 Hemoglobins Proteins 0.000 claims 2
- 229940006607 Hirudin Drugs 0.000 claims 2
- 229940088597 Hormone Drugs 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 231100000608 Immunotoxin Toxicity 0.000 claims 2
- 108010004484 Immunotoxins Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 2
- 108050003490 Insulin-like growth factor Proteins 0.000 claims 2
- 102000001617 Interferon Receptors Human genes 0.000 claims 2
- 108010054267 Interferon Receptors Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 229940047124 Interferons Drugs 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 102100016653 LALBA Human genes 0.000 claims 2
- 101700017573 LALBA Proteins 0.000 claims 2
- 102000010445 Lactoferrin Human genes 0.000 claims 2
- 108010063045 Lactoferrin Proteins 0.000 claims 2
- 229940078795 Lactoferrin Drugs 0.000 claims 2
- 102000016267 Leptin Human genes 0.000 claims 2
- 108010092277 Leptin Proteins 0.000 claims 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N Leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 2
- 229940040129 Luteinizing Hormone Drugs 0.000 claims 2
- 102000009151 Luteinizing Hormone Human genes 0.000 claims 2
- 108010073521 Luteinizing Hormone Proteins 0.000 claims 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 2
- 102100019916 MSTN Human genes 0.000 claims 2
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 2
- 108010056852 Myostatin Proteins 0.000 claims 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 2
- 108010008267 Nerve Growth Factors Proteins 0.000 claims 2
- 102000018886 Pancreatic Polypeptide Human genes 0.000 claims 2
- 108010052776 Pancreatic Polypeptide Proteins 0.000 claims 2
- 102000003982 Parathyroid hormone Human genes 0.000 claims 2
- 108090000445 Parathyroid hormone Proteins 0.000 claims 2
- 108010001014 Plasminogen Activators Proteins 0.000 claims 2
- 102000001938 Plasminogen Activators Human genes 0.000 claims 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 2
- 229920001451 Polypropylene glycol Polymers 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 102000017975 Protein C Human genes 0.000 claims 2
- 229960000856 Protein C Drugs 0.000 claims 2
- 108090000103 Relaxin Proteins 0.000 claims 2
- 102000003743 Relaxin Human genes 0.000 claims 2
- 102000013275 Somatomedins Human genes 0.000 claims 2
- 108010026080 Somatomedins Proteins 0.000 claims 2
- 229960005202 Streptokinase Drugs 0.000 claims 2
- 108010023197 Streptokinase Proteins 0.000 claims 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 2
- 108010012715 Superoxide Dismutase Proteins 0.000 claims 2
- 101710034269 TFPI Proteins 0.000 claims 2
- 102100008880 TFPI Human genes 0.000 claims 2
- 101700040544 TIMP1 Proteins 0.000 claims 2
- 102100002607 TIMP1 Human genes 0.000 claims 2
- 101700065146 TIMP2 Proteins 0.000 claims 2
- 102000003790 Thrombin receptors Human genes 0.000 claims 2
- 108090000166 Thrombin receptors Proteins 0.000 claims 2
- 102000012607 Thrombomodulin Human genes 0.000 claims 2
- 108010079274 Thrombomodulin Proteins 0.000 claims 2
- 102000011923 Thyrotropin Human genes 0.000 claims 2
- 108010061174 Thyrotropin Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 2
- 229960005356 Urokinase Drugs 0.000 claims 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 229940050528 albumin Drugs 0.000 claims 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 2
- 229940024142 alpha 1-Antitrypsin Drugs 0.000 claims 2
- 102000024070 binding proteins Human genes 0.000 claims 2
- 108091007650 binding proteins Proteins 0.000 claims 2
- 238000006065 biodegradation reaction Methods 0.000 claims 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 2
- 229950008486 carperitide Drugs 0.000 claims 2
- 230000022534 cell killing Effects 0.000 claims 2
- 239000002442 collagenase inhibitor Substances 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 102000027095 cytokine binding proteins Human genes 0.000 claims 2
- 108091007796 cytokine binding proteins Proteins 0.000 claims 2
- 230000009089 cytolysis Effects 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 150000004676 glycans Polymers 0.000 claims 2
- 125000003372 histidine group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 230000002637 immunotoxin Effects 0.000 claims 2
- 239000002596 immunotoxin Substances 0.000 claims 2
- 239000000411 inducer Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 235000021242 lactoferrin Nutrition 0.000 claims 2
- 229940039781 leptin Drugs 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 2
- 230000001394 metastastic Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108060005018 mobB Proteins 0.000 claims 2
- 108010045030 monoclonal antibodies Proteins 0.000 claims 2
- 102000005614 monoclonal antibodies Human genes 0.000 claims 2
- 230000017074 necrotic cell death Effects 0.000 claims 2
- 239000000199 parathyroid hormone Substances 0.000 claims 2
- 229960001319 parathyroid hormone Drugs 0.000 claims 2
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 claims 2
- 108091008117 polyclonal antibodies Proteins 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 150000004804 polysaccharides Polymers 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N propionic aldehyde Chemical group CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 239000003638 reducing agent Substances 0.000 claims 2
- 230000022983 regulation of cell cycle Effects 0.000 claims 2
- 239000002461 renin inhibitor Substances 0.000 claims 2
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 claims 2
- 230000002103 transcriptional Effects 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- 235000021241 α-lactalbumin Nutrition 0.000 claims 2
- TWNDEXHSZJGRBX-UHFFFAOYSA-N boric acid;N-methylmethanamine Chemical compound CNC.OB(O)O TWNDEXHSZJGRBX-UHFFFAOYSA-N 0.000 claims 1
- PWYPGEFOZYBWDP-UHFFFAOYSA-N boric acid;pyridine Chemical compound OB(O)O.C1=CC=NC=C1 PWYPGEFOZYBWDP-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 230000036678 protein binding Effects 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 claims 1
- 229910000033 sodium borohydride Inorganic materials 0.000 claims 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 claims 1
Claims (39)
- 生理活性ポリペプチド、および免疫グロブリンFc領域からなり、
該生理活性ポリペプチドと免疫グロブリンFc領域とが非ペプチド性重合体を介して共有結合によって連結された蛋白質結合体。 - 非ペプチド性重合体が、両末端の反応基を介して生理活性ポリペプチドおよび免疫グロブリンFc領域とそれぞれ共有結合によって連結される請求項1に記載の蛋白質結合体。
- 免疫グロブリンFc領域が非糖鎖化されることを特徴とする請求項1に記載の蛋白質結合体。
- 免疫グロブリンFc領域が、C H 1、C H 2、C H 3およびC H 4ドメインよりなる群から選択される1〜4個のドメインから構成される請求項1に記載の蛋白質結合体。
- 免疫グロブリンFc領域がヒンジ領域をさらに含む請求項4に記載の蛋白質結合体。
- 免疫グロブリンFc領域が、IgG、IgA、IgD、IgE、IgM、これらの組み合わせまたはこれらのハイブリッドのFc領域よりなる群から選択される請求項1に記載の蛋白質結合体。
- 免疫グロブリンFc領域が、IgG1、IgG2、IgG3、IgG4、これらの組み合わせまたはこれらのハイブリッドのFc領域よりなる群より選択される請求項6に記載の蛋白質結合体。
- 免疫グロブリンFc領域がIgG4 Fc領域である請求項7に記載の蛋白質結合体。
- 免疫グロブリンFc領域が、ヒト非糖鎖化IgG4 Fc領域である請求項8に記載の蛋白質結合体。
- 非ペプチド性重合体の反応基が、アルデヒド基、プロピオンアルデヒド基、ブチルアルデヒド基、マレイミド基およびスクシンイミド誘導体よりなる群から選択される請求項2に記載の蛋白質結合体。
- スクシンイミド誘導体が、スクシンイミジルプロピオネート、スクシンイミジルカルボキシメチル、ヒドロキシスクシンイミジルまたはスクシンイミジルカーボネートである請求項10に記載の蛋白質結合体。
- 非ペプチド性重合体が両末端に反応アルデヒド基の反応基を持つ請求項11に記載の蛋白質結合体。
- 非ペプチド性重合体の両末端がそれぞれ免疫グロブリンFc領域と生理活性ポリペプチドのアミノ末端、リジン残基、ヒスチジン残基またはシステイン残基の遊離反応基に結合している請求項1記載の蛋白質結合体。
- 非ペプチド性重合体が、ポリエチレングリコール単独重合体、ポリプロピレングリコール単独重合体、エチレングリコール−プロピレングリコール共重合体、ポリオキシエチル化ポリオール、ポリビニルアルコール、多糖類、デキストラン、ポリビニルエチルエーテル、生分解性高分子、脂質重合体、キチン類、ヒアルロン酸およびこれらの組み合わせよりなる群から選択されることを特徴とする請求項1に記載の蛋白質結合体。
- 非ペプチド性重合体がポリエチレングリコールである請求項14に記載の蛋白質結合体。
- 生理活性ポリペプチドが、ホルモン、サイトカイン、酵素、抗体、成長因子、転写調節因子、血液因子、ワクチン、構造蛋白質、リガンド蛋白質および受容体よりなる群から選択される請求項1に記載の蛋白質結合体。
- 生理活性ポリペプチドが、ヒト成長ホルモン、成長ホルモン放出ホルモン、成長ホルモン放出ペプチド、インターフェロン類、インターフェロン受容体類、コロニー刺激因子類、グルカゴン様ペプチド類、Gプロテイン関連受容体、インターロイキン類、インターロイキン受容体類、酵素類、インターロイキン結合蛋白質類、サイトカイン結合蛋白質類、マクロファージ活性因子、マクロファージペプチド、B細胞因子、T細胞因子、プロテインA、アレルギー抑制因子、細胞壊死糖蛋白質、免疫毒素、リンポ毒素、腫瘍壊死因子、腫瘍抑制因子、転移成長因子、アルファ−1アンチトリプシン、アルブミン、α−ラクトアルブミン、アポリポ蛋白質−E、赤血球生成因子、高糖鎖化赤血球生成因子、アンジオポエチン類、ヘモグロビン、トロンビン、トロンビン受容体活性ペプチド、トロンボモジュリン、血液因子VII、VIIa、VIII、IX、XIII、プラズミノゲン活性因子、フィブリン−結合ペプチド、ウロキナーゼ、ストレプトキナーゼ、ヒルジン、プロテインC、C−反応性蛋白質、レニン抑制剤、コラゲナーゼ抑制剤、スーパーオキシドジスムターゼ、レプチン、血小板由来成長因子、上皮細胞成長因子、表皮細胞成長因子、アンギオスタチン、アンギオテンシン、骨形成成長因子、骨形成促進蛋白質、カルシトニン、インスリン、アトリオペプチン、軟骨誘導因子、エルカトニン、結合組織活性因子、組織因子経路抑制剤、卵胞刺激ホルモン、黄体形成ホルモン、黄体形成ホルモン放出ホルモン、神経成長因子類、副甲状腺ホルモン、レラキシン、セクレチン、ソマトメジン、インスリン様成長因子、副腎皮質ホルモン、グルカゴン、コレシストキニン、膵臓ポリペプチド、ガストリン放出ペプチド、コルチコトロピン放出因子、甲状腺刺激ホルモン、オートタキシン、ラクトフェリン、ミオスタチン、受容体類、受容体拮抗物質、細胞表面抗原、ウイルス由来ワクチン抗原、モノクローナル抗体、ポリクローナル抗体よび抗体断片類よりなる群から選択される請求項16に記載の蛋白質結合体。
- 生理活性ポリペプチドが、ヒト成長ホルモン、インターフェロン−アルファ、顆粒球コロニー刺激因子、赤血球生成因子およびFab’抗体断片である請求項17に記載の蛋白質結合体。
- 請求項1に記載の蛋白質結合体を製造する方法であって、
(a)(a1)活性化された非ペプチド性重合体の一方の末端に免疫グロブリンFc領域または生理活性ポリペプチドを共有結合によって連結する段階と、
(a2)反応混合物から非ペプチド性重合体と連結された免疫グロブリンFc領域または生理活性ポリペプチドを含む連結体を分離する段階と、
(a3)分離された連結体の非ペプチド性重合体の他方の末端に免疫グロブリンFc領域または生理活性ポリペプチドを共有結合によって連結し、非ペプチド性重合体の両末端がそれぞれ免疫グロブリンFc領域および生理活性ポリペプチドと結合した蛋白質結合体を生成する段階と、
(b)上記蛋白質結合体を分離する段階と、を含み、
上記段階(a1)において、生理活性ポリペプチドと非ペプチド性重合体の反応モル比が1:2.5〜1:5であるか、または、免疫グロブリンFc領域と非ペプチド性重合体の反応モル比が1:5〜1:10であり、
上記段階(a3)において、段階(a2)で収得された連結体:免疫グロブリンFc領域または生理活性ポリペプチドの反応モル比が1:0.5〜1:20である製造方法。 - 段階(a1)および段階(a3)の反応が還元剤の存在下で行われる請求項19に記載の製造方法。
- 前記還元剤が、NaCNBH 3 、水素化ホウ素ナトリウム、ジメチルアミン硼酸塩またはピリジン硼酸塩よりなる群から選択される請求項20に記載の製造方法。
- 請求項1の蛋白質結合体およびこの薬剤学的に許容可能な担体を含む、生理活性ポリペプチドの生体内持続性および安定性増加用薬剤学的組成物。
- 非ペプチド性重合体が、両末端の反応基を介して生理活性ポリペプチドおよび免疫グロブリンFc領域とそれぞれ共有結合によって連結される請求項22に記載の薬剤学的組成物。
- 免疫グロブリンFc領域が非糖鎖化されることを特徴とする請求項22に記載の薬剤学的組成物。
- 免疫グロブリンFc領域が、C H 1、C H 2、C H 3およびC H 4ドメインよりなる群から選択される1〜4個のドメインから構成される請求項22に記載の薬剤学的組成物。
- 免疫グロブリンFc領域がヒンジ領域をさらに含む請求項25に記載の薬剤学的組成物。
- 免疫グロブリンFc領域が、IgG、IgA、IgD、IgE、IgM、これらの組み合わせまたはこれらのハイブリッドのFc領域よりなる群から選択される請求項22に記載の薬剤学的組成物。
- 免疫グロブリンFc領域が、IgG1、IgG2、IgG3、IgG4、これらの組み合わせまたはこれらのハイブリッドのFc領域よりなる群より選択される請求項27に記載の薬剤学的組成物。
- 免疫グロブリンFc領域がIgG4 Fc領域である請求項28に記載の薬剤学的組成物。
- 免疫グロブリンFc領域がヒト非糖鎖化IgG4 Fc領域である請求項29に記載の薬剤学的組成物。
- 非ペプチド性重合体の反応基が、アルデヒド基、プロピオンアルデヒド基、ブチルアルデヒド基、マレイミド基およびスクシンイミド誘導体よりなる群から選択される請求項23に記載の薬剤学的組成物。
- スクシンイミド誘導体が、スクシンイミジルプロピオネート、スクシンイミジルカルボキシメチル、ヒドロキシスクシンイミジルまたはスクシンイミジルカーボネートである請求項31に記載の薬剤学的組成物。
- 非ペプチド性重合体が両末端に反応アルデヒド基の反応基を持つ請求項32に記載の薬剤学的組成物。
- 非ペプチド性重合体の両末端が、それぞれ免疫グロブリンFc領域と生理活性ポリペプチドのアミノ末端、リジン残基、ヒスチジン残基またはシステイン残基の遊離反応基に結合している請求項22に記載の薬剤学的組成物。
- 非ペプチド性重合体が、ポリエチレングリコール単独重合体、ポリプロピレングリコール単独重合体、エチレングリコール−プロピレングリコール共重合体、ポリオキシエチル化ポリオール、ポリビニルアルコール、多糖類、デキストラン、ポリビニルエチルエーテル、生分解性高分子、脂質重合体、キチン類、ヒアルロン酸およびこれらの組み合わせよりなる群から選択されることを特徴とする請求項22に記載の薬剤学的組成物。
- 非ペプチド性重合体がポリエチレングリコールである請求項35に記載の薬剤学的組成物。
- 生理活性ポリペプチドが、ホルモン、サイトカイン、酵素、抗体、成長因子、転写調節因子、血液因子、ワクチン、構造蛋白質、リガンド蛋白質および受容体よりなる群から選択される請求項22に記載の薬剤学的組成物。
- 生理活性ポリペプチドが、ヒト成長ホルモン、成長ホルモン放出ホルモン、成長ホルモン放出ペプチド、インターフェロン類、インターフェロン受容体類、コロニー刺激因子類、グルカゴン様ペプチド類、Gプロテイン関連受容体、インターロイキン類、インターロイキン受容体類、酵素類、インターロイキン結合蛋白質類、サイトカイン結合蛋白質類、マクロファージ活性因子、マクロファージペプチド、B細胞因子、T細胞因子、プロテインA、アレルギー抑制因子、細胞壊死糖蛋白質、免疫毒素、リンポ毒素、腫瘍壊死因子、腫瘍抑制因子、転移成長因子、アルファ−1アンチトリプシン、アルブミン、α−ラクトアルブミン、アポリポ蛋白質−E、赤血球生成因子、高糖鎖化赤血球生成因子、アンジオポエチン類、ヘモグロビン、トロンビン、トロンビン受容体活性ペプチド、トロンボモジュリン、血液因子VII、VIIa、VIII、IX、XIII、プラズミノゲン活性因子、フィブリン−結合ペプチド、ウロキナーゼ、ストレプトキナーゼ、ヒルジン、プロテインC、C−反応性蛋白質、レニン抑制剤、コラゲナーゼ抑制剤、スーパーオキシドジスムターゼ、レプチン、血小板由来成長因子、上皮細胞成長因子、表皮細胞成長因子、アンギオスタチン、アンギオテンシン、骨形成成長因子、骨形成促進蛋白質、カルシトニン、インスリン、アトリオペプチン、軟骨誘導因子、エルカトニン、結合組織活性因子、組織因子経路抑制剤、卵胞刺激ホルモン、黄体形成ホルモン、黄体形成ホルモン放出ホルモン、神経成長因子類、副甲状腺ホルモン、レラキシン、セクレチン、ソマトメジン、インスリン様成長因子、副腎皮質ホルモン、グルカゴン、コレシストキニン、膵臓ポリペプチド、ガストリン放出ペプチド、コルチコトロピン放出因子、甲状腺刺激ホルモン、オートタキシン、ラクトフェリン、ミオスタチン、受容体類、受容体拮抗物質、細胞表面抗原、ウイルス由来ワクチン抗原、モノクローナル抗体、ポリクローナル抗体よび抗体断片類よりなる群から選択される請求項37に記載の薬剤学的組成物。
- 生理活性ポリペプチドが、ヒト成長ホルモン、インターフェロン−アルファ、顆粒球コロニー刺激因子、赤血球生成因子およびFab’抗体断片である請求項38に記載の薬剤学的組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20030080299 | 2003-11-13 | ||
KR10-2003-0080299 | 2003-11-13 | ||
PCT/KR2004/002944 WO2005047336A1 (en) | 2003-11-13 | 2004-11-13 | Protein complex using immunoglobulin fragment andmethod for the preparation thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011209594A Division JP2011256211A (ja) | 2003-11-13 | 2011-09-26 | 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007536211A JP2007536211A (ja) | 2007-12-13 |
JP2007536211A5 true JP2007536211A5 (ja) | 2008-01-31 |
JP4870569B2 JP4870569B2 (ja) | 2012-02-08 |
Family
ID=36589418
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006539396A Pending JP2007531513A (ja) | 2003-11-13 | 2004-11-13 | 薬物のキャリアとして有用なIgGFc断片およびその製造方法 |
JP2006539399A Active JP5216216B2 (ja) | 2003-11-13 | 2004-11-13 | 免疫グロブリンFc領域をキャリアとして含む薬剤学的組成物 |
JP2006539398A Active JP4870569B2 (ja) | 2003-11-13 | 2004-11-13 | 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法 |
JP2006539397A Active JP4762904B2 (ja) | 2003-11-13 | 2004-11-13 | 免疫グロブリン不変領域の量産方法 |
JP2011202199A Expired - Fee Related JP5425150B2 (ja) | 2003-11-13 | 2011-09-15 | 薬物のキャリアとして有用なIgGFc断片およびその製造方法 |
JP2011209594A Abandoned JP2011256211A (ja) | 2003-11-13 | 2011-09-26 | 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法 |
JP2012166208A Withdrawn JP2012224635A (ja) | 2003-11-13 | 2012-07-26 | 免疫グロブリンFc領域をキャリアとして含む薬剤学的組成物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006539396A Pending JP2007531513A (ja) | 2003-11-13 | 2004-11-13 | 薬物のキャリアとして有用なIgGFc断片およびその製造方法 |
JP2006539399A Active JP5216216B2 (ja) | 2003-11-13 | 2004-11-13 | 免疫グロブリンFc領域をキャリアとして含む薬剤学的組成物 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006539397A Active JP4762904B2 (ja) | 2003-11-13 | 2004-11-13 | 免疫グロブリン不変領域の量産方法 |
JP2011202199A Expired - Fee Related JP5425150B2 (ja) | 2003-11-13 | 2011-09-15 | 薬物のキャリアとして有用なIgGFc断片およびその製造方法 |
JP2011209594A Abandoned JP2011256211A (ja) | 2003-11-13 | 2011-09-26 | 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法 |
JP2012166208A Withdrawn JP2012224635A (ja) | 2003-11-13 | 2012-07-26 | 免疫グロブリンFc領域をキャリアとして含む薬剤学的組成物 |
Country Status (17)
Country | Link |
---|---|
US (13) | US8846874B2 (ja) |
EP (6) | EP1682584B1 (ja) |
JP (7) | JP2007531513A (ja) |
KR (5) | KR100775343B1 (ja) |
CN (4) | CN1723219B (ja) |
AT (3) | ATE555133T1 (ja) |
AU (2) | AU2004282984B2 (ja) |
BR (2) | BRPI0406605B8 (ja) |
CA (2) | CA2512657C (ja) |
DK (3) | DK1682583T3 (ja) |
ES (6) | ES2426169T3 (ja) |
HK (2) | HK1149570A1 (ja) |
MX (2) | MXPA05007210A (ja) |
PL (2) | PL2239273T3 (ja) |
PT (3) | PT2256134E (ja) |
RU (2) | RU2352583C2 (ja) |
WO (4) | WO2005047334A1 (ja) |
Families Citing this family (262)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7157555B1 (en) * | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
SI1581649T1 (sl) | 2002-12-20 | 2011-09-30 | Amgen Inc | Vezna sredstva, ki zavirajo miostatin |
ES2333598T5 (es) | 2003-05-06 | 2013-09-04 | Biogen Idec Hemophilia Inc | Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia. |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7850970B2 (en) | 2003-08-26 | 2010-12-14 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
US8263084B2 (en) * | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
KR101135244B1 (ko) * | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
WO2005047334A1 (en) * | 2003-11-13 | 2005-05-26 | Hanmi Pharmaceutical. Co., Ltd. | Igg fc fragment for a drug carrier and method for the preparation thereof |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
EP1759001B1 (en) | 2004-04-21 | 2011-04-13 | Enobia Pharma Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
US8143380B2 (en) * | 2004-07-08 | 2012-03-27 | Amgen Inc. | Therapeutic peptides |
KR100594607B1 (ko) * | 2004-11-03 | 2006-06-30 | 재단법인서울대학교산학협력재단 | 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법 |
US20090087478A1 (en) * | 2004-12-27 | 2009-04-02 | Progenics Pharmaceuticals (Nevada), Inc. | Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them |
CA2597346A1 (en) * | 2005-02-14 | 2006-08-17 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
KR100754667B1 (ko) * | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
SI1912675T1 (sl) * | 2005-07-25 | 2014-07-31 | Emergent Product Development Seattle, Llc | zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20 |
US8008453B2 (en) * | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
KR100824505B1 (ko) * | 2005-08-16 | 2008-04-22 | 한미약품 주식회사 | 개시 메티오닌 잔기가 제거된 면역글로불린 Fc 영역의대량 생산방법 |
EP1928910B1 (en) * | 2005-08-16 | 2014-01-15 | Hanmi Science Co., Ltd. | A method for the mass production of immunoglobulin fc region with deleted initial methionine residues |
CN101534865A (zh) * | 2005-10-19 | 2009-09-16 | Ibc药品公司 | 生物活性装配体的制备方法及其用途 |
JP2009512443A (ja) * | 2005-10-20 | 2009-03-26 | ザ スクリップス リサーチ インスチチュート | 免疫染色及び免疫標的化のためのFc標識化 |
AR056142A1 (es) * | 2005-10-21 | 2007-09-19 | Amgen Inc | Metodos para generar el anticuerpo igg monovalente |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
WO2007059782A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
US20070149458A1 (en) * | 2005-12-06 | 2007-06-28 | Amgen Inc. | Uses of myostatin antagonists |
CN101002945B (zh) | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
CN100475270C (zh) | 2006-01-20 | 2009-04-08 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
CA2654317A1 (en) * | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
PL2061803T5 (pl) | 2006-08-28 | 2023-03-27 | Ares Trading S.A. | Proces oczyszczania białek zawierających fc |
US20140147441A1 (en) * | 2006-09-12 | 2014-05-29 | The General Hospital Corporation | Compositions containing alpha-1-antitrypsin and methods for use |
US7820623B2 (en) | 2006-10-25 | 2010-10-26 | Amgen Inc. | Conjugated toxin peptide therapeutic agents |
US20080181903A1 (en) * | 2006-12-21 | 2008-07-31 | Pdl Biopharma, Inc. | Conjugate of natriuretic peptide and antibody constant region |
JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
CN101219219B (zh) * | 2007-01-10 | 2013-02-13 | 北京普罗吉生物科技发展有限公司 | 包含血管抑素或其片段的复合物、其制备方法及应用 |
US20080238882A1 (en) * | 2007-02-21 | 2008-10-02 | Ramesh Sivarajan | Symmetric touch screen system with carbon nanotube-based transparent conductive electrode pairs |
US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
TWI454479B (zh) | 2007-03-06 | 2014-10-01 | Amgen Inc | 變異之活動素受體多肽及其用途 |
CA2687141C (en) | 2007-05-22 | 2014-04-01 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
EP3173484B1 (en) * | 2007-05-30 | 2018-09-26 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
AU2008255350B2 (en) | 2007-05-31 | 2014-07-10 | Genmab A/S | Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals |
CN101835802B (zh) | 2007-06-01 | 2014-04-09 | 马里兰大学巴尔的摩分校 | 免疫球蛋白恒定区Fc受体结合剂 |
EP2162464A1 (en) * | 2007-06-06 | 2010-03-17 | Boehringer Ingelheim International GmbH | Natriuretic fusion proteins |
AU2008266952A1 (en) * | 2007-06-12 | 2008-12-24 | Trubion Pharmaceuticals, Inc. | Anti-CD20 therapeutic compositions and methods |
AU2008287195A1 (en) * | 2007-07-06 | 2009-02-19 | Emergent Product Development Seattle, Llc | Binding peptides having a C-terminally disposed specific binding domain |
US8492347B2 (en) * | 2007-10-17 | 2013-07-23 | The Regents Of The University Of California | Peptide for induction of immune tolerance as treatment for systemic lupus erythematosus |
EP2214700A4 (en) * | 2007-11-02 | 2012-08-22 | Janssen Biotech Inc | HALF-SYNTHETIC GLP-1 PEPTIDE FUSION CONSTRUCTS, METHOD AND USES |
PT2132228E (pt) * | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional |
US9636420B2 (en) | 2008-07-23 | 2017-05-02 | Hanmi Science Co., Ltd. | Polypeptide complex comprising non-peptidyl polymer having three functional ends |
RU2457856C2 (ru) * | 2008-08-05 | 2012-08-10 | Виктор Владимирович Чалов | Композиция, обладающая противовирусным и антимикробным действием, для перорального применения |
MX339137B (es) * | 2008-08-07 | 2016-05-13 | Ipsen Pharma Sas | Analogos de polipeptidos insulinotropicos dependientes de glucosa (gip) modificados en n terminal. |
US9072703B2 (en) | 2008-08-07 | 2015-07-07 | Ipsen Pharma S.A.S. | Glucose-dependent insulinotropic polypeptide analogues |
EP2987805A3 (en) * | 2008-08-07 | 2016-04-13 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
WO2010033216A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of nesiritide peptides |
WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
EP2344527A4 (en) * | 2008-10-31 | 2012-04-04 | Amgen Inc | MATERIALS AND METHODS FOR STEM CELL MOBILIZATION THROUGH A MULTIPLE PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR |
LT2370463T (lt) | 2008-11-26 | 2016-12-12 | Amgen Inc. | Stabilizuotas aktivino iib receptoriaus variantas |
WO2010065578A2 (en) * | 2008-12-04 | 2010-06-10 | Leukosight Inc. | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME |
US20100158893A1 (en) * | 2008-12-19 | 2010-06-24 | Baxter International Inc. | Systems and methods for obtaining immunoglobulin from blood |
KR20100084996A (ko) * | 2009-01-19 | 2010-07-28 | 한미홀딩스 주식회사 | 면역글로불린 단편을 이용한 생리활성 단백질 또는 펩타이드의 생산 방법 |
WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
CN102333872B (zh) | 2009-02-25 | 2014-07-09 | 默沙东公司 | 在糖工程化的酵母巴斯德毕赤酵母中对半乳糖同化途径的代谢工程化 |
JP5739865B2 (ja) * | 2009-03-24 | 2015-06-24 | バイエル・ヘルスケア・エルエルシー | 第viii因子変異体および使用の方法 |
AU2010239861B2 (en) | 2009-04-22 | 2013-07-11 | Alteogen, Inc | In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same |
US20120219538A1 (en) * | 2009-11-02 | 2012-08-30 | Therapeomic Ag | Stabilized protein formulations and use thereof |
US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
BR112012014962A2 (pt) | 2009-12-18 | 2016-04-05 | Exodos Life Sciences Ltd Partnership | métodos e composições para formulações líquidas e estáveis de fármacos |
CN107412737A (zh) * | 2010-01-19 | 2017-12-01 | 韩美科学株式会社 | 长效g‑csf缀合物的液体制剂 |
US8829163B2 (en) * | 2010-01-19 | 2014-09-09 | Hanmi Science Co., Ltd | Liquid formulations for long-acting erythropoietin conjugate |
WO2011093470A1 (ja) * | 2010-01-28 | 2011-08-04 | 協和発酵キリン株式会社 | Bone morphogenetic protein receptor 1B(BMPR1B)細胞外ドメイン又はその変異体を含む蛋白質を含有する骨疾患治療用医薬組成物 |
US8715963B2 (en) | 2010-02-24 | 2014-05-06 | Merck Sharp & Dohme Corp. | Method for increasing N-glycosylation site occupancy on therapeutic glycoproteins produced in Pichia pastoris |
CA2789738C (en) * | 2010-03-08 | 2021-03-09 | Ge Healthcare Bio-Sciences Ab | Immunoglobulin g fc region binding polypeptide |
AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
AR080993A1 (es) * | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
US9981017B2 (en) | 2010-04-02 | 2018-05-29 | Hanmi Science Co., Ltd. | Insulin conjugate using an immunoglobulin fragment |
AR081755A1 (es) * | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
CA2797865A1 (en) | 2010-04-30 | 2011-11-03 | Alexion Pharma International Sarl | Methods, compositions, and kits for the treatment of matrix mineralization disorders |
CA2800173C (en) | 2010-05-21 | 2019-05-14 | Ulrik Nielsen | Bi-specific fusion proteins |
KR101330868B1 (ko) * | 2010-06-08 | 2013-11-18 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체 |
KR20120002129A (ko) * | 2010-06-30 | 2012-01-05 | 한미홀딩스 주식회사 | 면역글로불린 단편을 이용한 제7인자(Factor Ⅶa)약물 결합체 |
KR101337797B1 (ko) * | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
KR101382593B1 (ko) * | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
AU2011282579B2 (en) | 2010-07-28 | 2014-10-23 | Gliknik Inc. | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions |
KR101333958B1 (ko) * | 2010-10-20 | 2013-11-27 | 주식회사 한독 | 인간 인터루킨-1 수용체 길항제-하이브리드 Fc 융합단백질 |
WO2012053828A2 (ko) * | 2010-10-20 | 2012-04-26 | 주식회사 한독약품 | 인간 인터루킨-1 수용체 길항제-하이브리드 Fc 융합단백질 |
KR101303388B1 (ko) * | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
EP2465536A1 (en) | 2010-12-14 | 2012-06-20 | CSL Behring AG | CD89 activation in therapy |
JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
CA2823066A1 (en) | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
JP6162606B2 (ja) | 2011-01-14 | 2017-07-12 | レッドウッド バイオサイエンス, インコーポレイテッド | アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法 |
CN102309765B (zh) * | 2011-02-28 | 2013-10-16 | 北京韩美药品有限公司 | 包含免疫球蛋白Fc片段作为载体的长效抗凝多肽及其制备方法 |
EP2694092B1 (en) | 2011-04-08 | 2017-01-04 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
CN102807619B (zh) * | 2011-06-03 | 2016-08-03 | 北京韩美药品有限公司 | 含有免疫球蛋白Fc片段和粒细胞-巨噬细胞集落刺激因子的复合物及其药物组合物 |
EP3434687B1 (en) | 2011-06-10 | 2021-03-10 | Hanmi Science Co., Ltd. | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
CN109306015B (zh) * | 2011-06-17 | 2022-04-26 | 韩美科学株式会社 | 包括泌酸调节肽和免疫球蛋白片段的结合物以及其应用 |
EP2723370A4 (en) * | 2011-06-24 | 2015-06-03 | Univ Colorado Regents | COMPOSITIONS, PROCESS AND USE OF ALPHA-1-ANTITRYPHIN FUSION MOLECULES |
IL312872A (en) * | 2011-06-28 | 2024-07-01 | Inhibrx Inc | Methods for purifying fusion proteins containing serphin |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
MX356433B (es) * | 2011-06-28 | 2018-05-29 | Inhibrx Lp | Polipéptidos de fusión con domino de proteína ácida del suero, y métodos de uso de los mismos. |
WO2013036032A1 (en) | 2011-09-05 | 2013-03-14 | Hanmi Science Co., Ltd. | A pharmaceutical composition for treating cancer, comprising interferon alpha conjugate |
UY34347A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
JP6108630B2 (ja) * | 2011-10-06 | 2017-04-05 | ハンミ サイエンス カンパニー リミテッドHanmi Science Co.,Ltd. | 血液凝固因子VII及びVIIa誘導体、それらを含む結合体及び複合体、並びにそれらの使用 |
JP6158090B2 (ja) * | 2011-10-31 | 2017-07-05 | ダニエル・ジェイ・カポン | 非ペプチドヒンジ部含有フレキシブル抗体様分子 |
KR20130049671A (ko) * | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
AU2012364736A1 (en) | 2011-12-19 | 2014-07-24 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
CN103172745A (zh) * | 2011-12-21 | 2013-06-26 | 北京韩美药品有限公司 | 包含免疫球蛋白Fc片段的长效人内皮抑素 |
KR102041412B1 (ko) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Fc 단편 유도체 |
KR101895047B1 (ko) | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
CA2862979A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
US10774132B2 (en) | 2012-01-09 | 2020-09-15 | The Scripps Research Instittue | Ultralong complementarity determining regions and uses thereof |
KR20140137347A (ko) | 2012-01-10 | 2014-12-02 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도 |
WO2013113008A1 (en) | 2012-01-26 | 2013-08-01 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
EP2636681A1 (en) | 2012-03-09 | 2013-09-11 | CSL Behring AG | Process for enriching IgA |
EP2636684A1 (en) | 2012-03-09 | 2013-09-11 | CSL Behring AG | Prevention of infection |
AU2013201393B2 (en) | 2012-03-09 | 2015-08-27 | Csl Behring Ag | Compositions |
US10064951B2 (en) * | 2012-03-30 | 2018-09-04 | Hanmi Science Co., Ltd. | Liquid formulation of highly concentrated long-acting human growth hormone conjugate |
US9809641B2 (en) * | 2012-04-23 | 2017-11-07 | Nrl Pharma, Inc. | Lactoferrin fusion protein and method for preparation thereof |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
DK2859017T3 (da) | 2012-06-08 | 2019-05-13 | Sutro Biopharma Inc | Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf |
US9732161B2 (en) | 2012-06-26 | 2017-08-15 | Sutro Biopharma, Inc. | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
WO2014001325A1 (en) * | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
RU2639287C2 (ru) | 2012-06-27 | 2017-12-20 | Ф. Хоффманн-Ля Рош Аг | Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
AR091902A1 (es) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
US10441665B2 (en) | 2012-07-25 | 2019-10-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long acting insulinotropic peptide conjugate |
AR092862A1 (es) | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
US9683044B2 (en) | 2012-08-20 | 2017-06-20 | Gliknik Inc. | Molecules with antigen binding and polyvalent FC gamma receptor binding activity |
ES2728864T3 (es) | 2012-08-31 | 2019-10-29 | Sutro Biopharma Inc | Aminoácidos modificados que comprenden un grupo azido |
US9561275B2 (en) | 2012-09-14 | 2017-02-07 | The Johns Hopkins University | Compositions and methods for rendering tumor cells susceptible to CD8+ T cell-mediated killing |
EP2895496B1 (en) | 2012-09-14 | 2017-06-07 | F. Hoffmann-La Roche AG | Method for the production and selection of molecules comprising at least two different entities and uses thereof |
CA2890324C (en) | 2012-11-06 | 2021-02-23 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
KR101993393B1 (ko) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
EP2943512A4 (en) * | 2013-01-11 | 2016-06-01 | California Inst Biomedical Res | FUSION BOVINE ANTIBODIES |
CN103217489B (zh) * | 2013-01-15 | 2016-03-09 | 珠海市丽珠单抗生物技术有限公司 | 一种测定蛋白纯化工艺过程中样品的糖基化和末端修饰情况的方法 |
KR102073748B1 (ko) * | 2013-01-31 | 2020-02-05 | 한미약품 주식회사 | 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법 |
EP3985024A1 (en) | 2013-02-01 | 2022-04-20 | Atara Biotherapeutics, Inc. | Anti-activin-a compounds for the treatment of ovarian cancer |
CA2900814A1 (en) | 2013-02-22 | 2014-08-28 | Zoetis Services Llc | In ovo administration of growth factors for improving poultry performance |
KR102136336B1 (ko) * | 2013-03-05 | 2020-07-22 | 한미약품 주식회사 | 생리활성 폴리펩타이드 결합체의 고수율 생산을 위한 개선된 제조 방법 |
TW201513880A (zh) | 2013-03-11 | 2015-04-16 | Novo Nordisk As | 生長激素化合物 |
US20140271641A1 (en) * | 2013-03-14 | 2014-09-18 | University Of Guelph | Thrombospondin-1 polypeptides and methods of using same |
DK3460054T3 (da) | 2013-03-15 | 2021-01-18 | Atyr Pharma Inc | Histidyl-tRNA-syntetase-Fc-konjugater |
TWI683666B (zh) | 2013-03-15 | 2020-02-01 | 美商百歐維拉提夫治療公司 | 因子ix多肽調配物 |
KR101895634B1 (ko) * | 2013-05-31 | 2018-09-05 | 한미약품 주식회사 | 변이된 힌지 영역을 포함하는 IgG4 Fc 단편 |
ES2658039T3 (es) | 2013-07-10 | 2018-03-08 | Sutro Biopharma, Inc. | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
AR096891A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
AR096890A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn |
WO2015010100A2 (en) | 2013-07-18 | 2015-01-22 | Fabrus, Inc. | Humanized antibodies with ultralong complementarity determining regions |
MA38873B1 (fr) | 2013-07-31 | 2018-11-30 | Amgen Inc | Constructions contenant le facteur 15 de différentiation de croissance (gdf-15) |
US20150093399A1 (en) | 2013-08-28 | 2015-04-02 | Bioasis Technologies, Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
SI3041513T1 (sl) | 2013-09-08 | 2020-11-30 | Kodiak Sciences Inc. | Zwitterionski polimerni konjugati faktorja VIII |
EP3043810B1 (en) | 2013-09-09 | 2019-10-23 | CanImGuide Therapeutics AB | Immune system modulators |
MX2016003705A (es) | 2013-09-27 | 2016-05-16 | Hanmi Pharm Ind Co Ltd | Formulacion de un conjugado de hormona del crecimiento humana de accion prolongada. |
WO2015047890A1 (en) * | 2013-09-30 | 2015-04-02 | 3M Innovative Properties Company | Fibers and wipes with epoxidized fatty ester disposed thereon, and methods |
WO2015070210A1 (en) | 2013-11-11 | 2015-05-14 | Wake Forest University Health Sciences | Epha3 and multi-valent targeting of tumors |
PE20161153A1 (es) | 2014-01-20 | 2016-10-27 | Hanmi Pharm Ind Co Ltd | Insulina de accion prolongada y uso de la misma |
WO2015112597A1 (en) * | 2014-01-21 | 2015-07-30 | Belmont Biosciences, Inc. | Variants of igg fc with limited amine groups that retain functional properties |
ES2897935T3 (es) * | 2014-03-31 | 2022-03-03 | Hanmi Pharm Ind Co Ltd | Método para mejorar la solubilidad de proteína y péptido mediante el uso del enlace a un fragmento Fc de inmunoglobulina |
RS58440B1 (sr) * | 2014-04-11 | 2019-04-30 | Medimmune Llc | Konjugovana jedinjenja koja sadrže cistein-projektovana antitela |
AU2015254818A1 (en) * | 2014-04-28 | 2016-11-17 | The National Institute for Biotechnology in the Negev Ltd. | Variants of DR3 and use thereof |
KR20150133576A (ko) * | 2014-05-20 | 2015-11-30 | 삼성전자주식회사 | 화학적 개질된 표적화 단백질 및 그의 이용 |
AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
AR100695A1 (es) | 2014-05-30 | 2016-10-26 | Hanmi Pharm Ind Co Ltd | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón |
AU2015279316B2 (en) | 2014-06-27 | 2021-03-04 | Innate Pharma | Multispecific NKp46 binding proteins |
WO2015197598A2 (en) * | 2014-06-27 | 2015-12-30 | Innate Pharma | Multispecific antigen binding proteins |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
CN106536540A (zh) | 2014-07-24 | 2017-03-22 | 基因泰克公司 | 将试剂缀合至含有至少一个三硫键的蛋白质中的巯基部分的方法 |
TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
KR20210013299A (ko) | 2014-10-17 | 2021-02-03 | 코디악 사이언시스 인코포레이티드 | 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트 |
MX2017007392A (es) | 2014-12-05 | 2019-01-24 | Alexion Pharma Inc | Tratamiento de convulsiones con fosfatasa alcalina recombinante. |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
US11135271B2 (en) | 2014-12-30 | 2021-10-05 | Hanmi Pharm. Co., Ltd. | Glucagon derivatives with improved stability |
JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
WO2016144650A1 (en) | 2015-03-06 | 2016-09-15 | Canimguide Therapeutics Ab | Immune system modulators and compositions |
KR20170141215A (ko) | 2015-04-06 | 2017-12-22 | 악셀레론 파마 인코포레이티드 | 싱글-암 유형 i과 유형 ii 수용체 융합 단백질들 및 이들의 용도 |
RU2733492C2 (ru) * | 2015-04-22 | 2020-10-02 | Байоджен Ма Инк. | Новые гибридные ActRIIB белки-ловушки лигандов для лечения заболеваний, связанных с мышечной атрофией |
JP2018518945A (ja) * | 2015-04-29 | 2018-07-19 | メディオラヌム・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ | 可溶性キメラインターロイキン−10受容体およびその療法使用 |
CN107743494B (zh) | 2015-06-02 | 2022-04-29 | 诺和诺德股份有限公司 | 具有极性重组延伸体的胰岛素 |
BR112017026713A2 (pt) * | 2015-06-12 | 2018-08-28 | Ubi Pharma Inc | proteínas de fusão de imunoglobulina e usos das mesmas |
US11820807B2 (en) * | 2015-06-12 | 2023-11-21 | Ubi Pharma Inc | Immunoglobulin fusion proteins and uses thereof |
JP6971153B2 (ja) | 2015-06-23 | 2021-11-24 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的nkエンゲイジャータンパク質 |
EP3322437B1 (en) | 2015-06-30 | 2024-01-17 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
ES2978112T3 (es) | 2015-07-24 | 2024-09-05 | Hanmi Pharmaceutical Co Ltd | Método de preparación de un conjugado polipeptídico fisiológicamente activo |
AU2016308624B2 (en) | 2015-08-17 | 2022-06-23 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
EP3352760A4 (en) | 2015-09-21 | 2019-03-06 | Aptevo Research and Development LLC | CD3 BINDING POLYPEPTIDES |
KR102231217B1 (ko) * | 2015-09-24 | 2021-03-24 | 한미약품 주식회사 | 면역글로불린 단편의 특정 위치를 연결 부위로 이용한 단백질 결합체 |
TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Fc區之蛋白質接合物 |
JP6868617B2 (ja) | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ(tnsalp)酵素補充療法に有効な投薬計画の特定 |
MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
EP4183451A1 (en) * | 2015-10-01 | 2023-05-24 | Heat Biologics, Inc. | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
CN115960249A (zh) | 2015-10-02 | 2023-04-14 | 银溪制药股份有限公司 | 用于组织修复的双特异性治疗性蛋白质 |
US20170095577A1 (en) * | 2015-10-06 | 2017-04-06 | Washington University | Noninvasive imaging of focal atherosclerotic lesions using fluorescence molecular tomography |
EP3368062A4 (en) | 2015-10-30 | 2019-07-03 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT |
CN108430511B (zh) * | 2015-12-21 | 2021-06-04 | 合肥立方制药股份有限公司 | 一种药物设计方法和获得的药物及其应用 |
IL290457B1 (en) | 2015-12-30 | 2024-10-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
KR20170079409A (ko) * | 2015-12-30 | 2017-07-10 | 한미약품 주식회사 | 지속형 인간 성장 호르몬 결합체의 신규 액상 제제 |
BR112018013525A2 (pt) | 2015-12-31 | 2018-12-04 | Hanmi Pharm. Co., Ltd. | conjugado de longa atuação de agonista de receptor de glucagon/glp-1/gip triplo e composição farmacêutica |
WO2017132617A1 (en) | 2016-01-27 | 2017-08-03 | Sutro Biopharma, Inc. | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
AR107483A1 (es) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
US11065306B2 (en) | 2016-03-08 | 2021-07-20 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS |
EP3436052A4 (en) | 2016-04-01 | 2019-10-09 | Alexion Pharmaceuticals, Inc. | TREATMENT OF MUSCLE WEAKNESS USING ALKALINE PHOSPHATASES |
WO2017189432A1 (en) | 2016-04-26 | 2017-11-02 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
JP7020403B2 (ja) | 2016-05-02 | 2022-02-16 | 味の素株式会社 | アジド基含有Fcタンパク質 |
CN106008722B (zh) * | 2016-05-13 | 2019-10-15 | 未名生物医药有限公司 | 一种重组β-hNGF-Fc融合蛋白、制备方法及用途 |
US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
CA3026420A1 (en) | 2016-06-07 | 2017-12-14 | Gliknik Inc. | Cysteine-optimized stradomers |
SG11201811697SA (en) | 2016-06-29 | 2019-01-30 | Hanmi Pharmaceutical Co Ltd | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
US11116821B2 (en) | 2016-08-18 | 2021-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
JOP20190019A1 (ar) * | 2016-08-30 | 2019-02-12 | Genexine Inc | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) |
BR112019005637A2 (pt) | 2016-09-23 | 2019-07-30 | Hanmi Pharm Ind Co Ltd | análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso |
US20200078470A1 (en) * | 2016-12-05 | 2020-03-12 | Hanmi Pharm. Co., Ltd. | Conjugate with attenuated immune response |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
AU2017371179B2 (en) | 2016-12-09 | 2022-07-14 | Gliknik Inc. | Manufacturing optimization of GL-2045, a multimerizing stradomer |
KR102645064B1 (ko) * | 2017-02-03 | 2024-03-08 | 한미약품 주식회사 | 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도 |
EP3585409A4 (en) | 2017-02-27 | 2020-12-02 | Shattuck Labs, Inc. | CHEMERICAL PROTEINS BASED ON CSF1R |
AU2018223821B2 (en) | 2017-02-27 | 2022-05-19 | Shattuck Labs, Inc. | TIGIT- and LIGHT-based chimeric proteins |
CA3054899A1 (en) | 2017-03-23 | 2018-09-27 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
EP3600383A4 (en) | 2017-03-31 | 2020-10-28 | Alexion Pharmaceuticals, Inc. | METHODS FOR TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS |
JP2020513019A (ja) * | 2017-04-05 | 2020-04-30 | ノヴォ ノルディスク アー/エス | オリゴマー伸長インスリン−Fcコンジュゲート |
US11767520B2 (en) | 2017-04-20 | 2023-09-26 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
CN110770251A (zh) * | 2017-04-20 | 2020-02-07 | 诺和诺德股份有限公司 | 纯化白蛋白融合蛋白的方法 |
CN109206522B (zh) * | 2017-07-07 | 2021-11-09 | 北京三有利和泽生物科技有限公司 | 一种长效抗凝血融合蛋白及其应用 |
KR20190038456A (ko) * | 2017-09-29 | 2019-04-08 | 한미약품 주식회사 | 효력이 향상된 지속성 단백질 결합체 |
JP6566324B2 (ja) * | 2017-09-29 | 2019-08-28 | サイデン化学株式会社 | 粘着シート |
CA3076369A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
KR102167827B1 (ko) * | 2017-12-20 | 2020-10-20 | 주식회사 알테오젠 | 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질 |
CN108218998A (zh) * | 2017-12-31 | 2018-06-29 | 武汉班科生物技术股份有限公司 | 一种突变型人源IgG的Fc片段及其制备方法与应用 |
KR101974305B1 (ko) * | 2018-02-14 | 2019-04-30 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
JP7328243B2 (ja) * | 2018-03-26 | 2023-08-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 治療薬を試験するためのヒト化げっ歯類 |
KR102209108B1 (ko) | 2018-03-27 | 2021-01-28 | 국립암센터 | Oct4 기능 저해용 펩티드를 포함하는 줄기세포성 억제용 조성물 |
EP3773684A1 (en) | 2018-03-30 | 2021-02-17 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
CN111954537A (zh) | 2018-04-09 | 2020-11-17 | 美国安进公司 | 生长分化因子15融合蛋白 |
US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
EP3978518A4 (en) * | 2019-04-23 | 2022-11-02 | Lg Chem, Ltd. | FUSION POLYPEPTIDE COMPRISING FC REGION OF IMMUNOGLOBULIN AND GDF15 |
US11267858B2 (en) * | 2019-05-31 | 2022-03-08 | Spectrum Pharmaceuticals, Inc. | Methods of treatment using G-CSF protein complex |
CN112142850A (zh) * | 2019-06-27 | 2020-12-29 | 深圳市卫光生物制品股份有限公司 | 人神经生长因子-乳铁蛋白重组蛋白及用途 |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
CN110669134A (zh) * | 2019-10-15 | 2020-01-10 | 广东菲鹏生物有限公司 | IgM-FC片段、IgM-FC抗体及制备方法和应用 |
AU2020400805B2 (en) * | 2019-12-11 | 2024-03-28 | Lg Chem, Ltd. | Fusion polypeptide comprising GDF15 and polypeptide region capable of O-glycosylation |
CN111153996B (zh) * | 2020-01-10 | 2021-12-14 | 苏州睿瀛生物技术有限公司 | G蛋白偶联受体的抗体及其制备方法和g蛋白偶联受体试剂盒 |
CN111505291B (zh) * | 2020-04-14 | 2023-04-25 | 山东省千佛山医院 | 一种排除巨酶分子对血清酶浓度检测带来干扰的方法 |
BR112022023738A2 (pt) | 2020-05-22 | 2023-01-31 | Hanmi Pharm Ind Co Ltd | Formulação líquida |
CN112098639B (zh) * | 2020-09-21 | 2024-01-02 | 天津医科大学 | 以氧化石墨烯为载体的二抗的合成及应用 |
EP4291224A1 (en) | 2021-02-12 | 2023-12-20 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
WO2023147489A2 (en) * | 2022-01-28 | 2023-08-03 | argenx BV | Anti-musk antibodies for use in treating neuromuscular disorders |
IL315251A (en) * | 2022-03-03 | 2024-10-01 | The Trustees Of The Univ Of Pennsylvania | Viral vectors encoding parathyroid hormone fusions and their uses for the treatment of hypoparathyroidism |
CN114588315A (zh) * | 2022-03-14 | 2022-06-07 | 东莞市人民医院 | 抗炎蛋白涂层的制备方法、生物工程功能材料及其应用 |
WO2024123675A2 (en) * | 2022-12-05 | 2024-06-13 | Alexion Pharmaceuticals, Inc. | Taci-fc fusion proteins for multifunctional inhibition of baff, april, and neonatal fc receptor |
WO2024148240A1 (en) | 2023-01-06 | 2024-07-11 | Lassen Therapeutics 1, Inc. | ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE |
WO2024148241A1 (en) | 2023-01-06 | 2024-07-11 | Lassen Therapeutics 1, Inc. | Anti-il-18bp antibodies |
WO2024148243A1 (en) | 2023-01-06 | 2024-07-11 | Lassen Therapeutics 1, Inc. | Anti-il-18bp antibodies |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
GB8504099D0 (en) * | 1985-02-18 | 1985-03-20 | Wellcome Found | Physiologically active substances |
JPS62153300A (ja) * | 1985-12-26 | 1987-07-08 | Teijin Ltd | ヒト免疫グロブリンGFc領域蛋白質およびその製造方法 |
JPH0728746B2 (ja) | 1986-02-28 | 1995-04-05 | 理化学研究所 | 新規プラスミド、微生物細胞及びヒト免疫グロブリンG Fc領域蛋白質の製造法 |
US5643758A (en) * | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
JPS63245691A (ja) | 1987-03-31 | 1988-10-12 | Teijin Ltd | ヒト免疫グロブリンGFc領域蛋白質およびその製造方法 |
JPS63290899A (ja) | 1987-05-22 | 1988-11-28 | Takeda Chem Ind Ltd | ヒトIgEFc蛋白質のフラグメントおよびその製造法 |
US6710169B2 (en) * | 1987-10-02 | 2004-03-23 | Genentech, Inc. | Adheson variants |
DE3889546T2 (de) | 1987-12-21 | 1994-09-08 | Univ Toledo | Transformation von keimenden pflanzensamen mit hilfe von agrobacterium. |
US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US6004781A (en) | 1988-01-22 | 1999-12-21 | The General Hospital Corporation | Nucleic acid encoding Ig-CD4 fusion proteins |
GB8824869D0 (en) | 1988-10-24 | 1988-11-30 | Stevenson G T | Synthetic antibody |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US6307025B1 (en) | 1989-04-28 | 2001-10-23 | Biogen, Inc. | VCAM fusion proteins and DNA coding therefor |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US6541610B1 (en) | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
GB9009106D0 (en) | 1990-04-23 | 1990-06-20 | 3I Res Expl Ltd | Processes and intermediates for synthetic antibody derivatives |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US7253264B1 (en) * | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
ES2120949T4 (es) | 1990-06-28 | 2011-12-29 | Sanofi-Aventis Deutschland Gmbh 50% | Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo. |
US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
US5191066A (en) | 1990-12-07 | 1993-03-02 | Abbott Laboratories | Site-specific conjugation of immunoglobulins and detectable labels |
JP3670276B2 (ja) | 1991-02-08 | 2005-07-13 | プロゲニクス・ファーマスーティカルズ、インコーポレイテッド | CD4― ガンマ・2キメラ及びCD4 ― IgG2・キメラ |
GEP20033082B (en) | 1991-03-15 | 2003-10-27 | Amgen Inc | Pegylation of Polypeptides |
CA2585487A1 (fr) * | 1991-04-17 | 1992-10-29 | Medarex Inc. | Polypeptides hydrosolubles ayant une haute affinite pour les interferons .alpha. et .beta. |
EP0533006A1 (en) | 1991-09-18 | 1993-03-24 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Chimaeric interleukin 5-receptor/immunoglobulin polypeptides |
US20020037558A1 (en) | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
GB9206422D0 (en) * | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
JPH0640945A (ja) | 1992-07-23 | 1994-02-15 | Kureha Chem Ind Co Ltd | Fcフラグメント結合抗腫瘍剤 |
JPH08503125A (ja) * | 1992-08-07 | 1996-04-09 | プロジェニクス・ファーマスーティカルス・インコーポレーテッド | 非ペプチジル成分と複合化されたCD4−ガンマ2およびCD4−IgG2免疫複合体、並びにその使用 |
IT1263831B (it) | 1993-01-29 | 1996-09-04 | Paolo Chiesi | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina |
US6482919B2 (en) | 1993-02-01 | 2002-11-19 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5470952A (en) | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
US6410008B1 (en) * | 1994-12-12 | 2002-06-25 | Beth Israel Hospital Association | Chimeric IL-10 proteins and uses thereof |
US6030613A (en) * | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
WO1996028475A1 (fr) | 1995-03-10 | 1996-09-19 | Nakamura, Toshikazu | Facteur de croissance des hepatocytes modifie a l'aide de polyethylene glycol |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
GB9511935D0 (en) | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
HUP9900017A3 (en) * | 1995-09-21 | 2001-08-28 | Andaris Ltd Ruddington | Transcytosis vehicles and enhancers for drug delivery |
US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
KR19980038061A (ko) | 1996-11-23 | 1998-08-05 | 유우준 | 음식물 쓰레기 수분분리 처리장치 |
US7122636B1 (en) * | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
MY118835A (en) * | 1997-04-18 | 2005-01-31 | Ipsen Pharma Biotech | Sustained release compositions and the process for their preparation |
US5990237A (en) * | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
AU8182298A (en) | 1997-07-10 | 1999-02-08 | Beth Israel Deaconess Medical Center | Recombinant erythropoietin / immunoglobulin fusion proteins |
US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
US6451986B1 (en) * | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
KR100316347B1 (ko) | 1998-09-15 | 2002-08-27 | 한미약품(주) | 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법 |
IL142350A0 (en) * | 1998-10-16 | 2002-03-10 | Biogen Inc | Interferon-beta fusion proteins and pharmaceutical compositions containing the same |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
CA2356401A1 (en) * | 1999-01-07 | 2000-07-13 | Lexigen Pharmaceuticals, Corp. | Expression and export of anti-obesity proteins as fc fusion proteins |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
AU3224700A (en) | 1999-02-08 | 2000-08-25 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
US20040266673A1 (en) * | 2002-07-31 | 2004-12-30 | Peter Bakis | Long lasting natriuretic peptide derivatives |
CA2372400C (en) | 1999-05-19 | 2010-04-27 | Lexigen Pharmaceuticals Corp. | Expression and export of interferon-alpha proteins as fc fusion proteins |
US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
EP1194451A1 (en) | 1999-07-02 | 2002-04-10 | Genentech, Inc. | Fusion peptides comprising a peptide ligand domain and a multimerization domain |
JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
EP1200124B1 (en) | 1999-07-13 | 2008-09-10 | Bolder Biotechnology, Inc. | Erythropoietin-immunoglobulin fusion proteins |
KR100360594B1 (ko) | 2000-01-19 | 2002-11-13 | 한미약품공업 주식회사 | 인간 인터페론 알파의 발현 분비벡터 및 이를 이용한인터페론 알파의 생산 방법 |
MXPA02010324A (es) | 2000-04-21 | 2003-04-25 | Amgen Inc | Derivados de peptidos apo-ai/aii. |
US6756480B2 (en) * | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
US20020168367A1 (en) * | 2000-04-28 | 2002-11-14 | Planet Biotechnology Incorporated | Novel immunoadhesins for treating and preventing viral and bacterial diseases |
US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
DE10021731B4 (de) | 2000-05-04 | 2005-12-08 | Aventis Pharma Deutschland Gmbh | Cyclipostine, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung derselben |
US6417237B1 (en) | 2000-06-08 | 2002-07-09 | The Board Of Trustees Of The University Of Illinois | Macromolecular drug complexes and compositions containing the same |
KR20080085082A (ko) * | 2000-12-07 | 2008-09-22 | 일라이 릴리 앤드 캄파니 | Glp-1 융합 단백질 |
DE60117601T2 (de) | 2000-12-14 | 2006-11-16 | Genentech Inc., San Francisco | Bakterielle wirtstämme |
US6979556B2 (en) | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
EP1392826A2 (en) | 2001-01-18 | 2004-03-03 | MERCK PATENT GmbH | Bifunctional fusion proteins with glucocerebrosidase activity |
WO2002066514A2 (en) * | 2001-02-19 | 2002-08-29 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
KR100566911B1 (ko) | 2001-06-25 | 2006-04-03 | 주식회사 삼양사 | 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체 |
WO2003002144A1 (en) | 2001-06-26 | 2003-01-09 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
US20030026764A1 (en) | 2001-07-31 | 2003-02-06 | Immunomedics, Inc. | Polymeric delivery systems |
US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
US6797493B2 (en) * | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
US7125843B2 (en) * | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
KR100811138B1 (ko) | 2001-11-13 | 2008-03-07 | 오리온피디피주식회사 | 저온소성세라믹기판을 이용한 다층회로기판의 제조방법과 이에 의해 제조된 다층회로기판 |
US20030211078A1 (en) * | 2001-12-07 | 2003-11-13 | Heavner George A. | Pseudo-antibody constructs |
US20040110226A1 (en) * | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
EP1572936A2 (en) | 2002-03-05 | 2005-09-14 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
EP1487992A4 (en) | 2002-03-15 | 2007-10-31 | Brigham & Womens Hospital | CENTRAL AIRWAY DELIVERY FOR SYSTEMIC DRUG DELIVERY |
US20030191056A1 (en) * | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
WO2004024889A2 (en) * | 2002-09-16 | 2004-03-25 | Elusys Therapeutics, Inc. | Production of bispecific molecules using polyethylene glycol linkers |
EP1578447A4 (en) * | 2002-10-31 | 2009-06-03 | Genentech Inc | METHODS AND COMPOSITIONS THAT CAN INCREASE ANTIBODY PRODUCTION |
SI1581649T1 (sl) | 2002-12-20 | 2011-09-30 | Amgen Inc | Vezna sredstva, ki zavirajo miostatin |
WO2004064731A2 (en) | 2003-01-14 | 2004-08-05 | University Of Washington | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues |
US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
KR20040083268A (ko) | 2003-03-21 | 2004-10-01 | 한미약품 주식회사 | 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법 |
ES2333598T5 (es) | 2003-05-06 | 2013-09-04 | Biogen Idec Hemophilia Inc | Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia. |
TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
WO2004108885A2 (en) | 2003-05-06 | 2004-12-16 | Syntonix Pharmaceuticals, Inc. | Fc chimeric proteins with anti-hiv drugs |
CA2527878A1 (en) * | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
WO2005047334A1 (en) | 2003-11-13 | 2005-05-26 | Hanmi Pharmaceutical. Co., Ltd. | Igg fc fragment for a drug carrier and method for the preparation thereof |
BRPI0507174A (pt) | 2004-01-28 | 2008-04-01 | Syntonix Pharmaceuticals Inc | proteìnas de fusão hormÈnio-fc (fsh-fc) heterodiméricas estimuladoras de folìculo para o tratamento da infertilidade |
AU2005289594B2 (en) * | 2004-09-27 | 2012-02-02 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
KR100594607B1 (ko) | 2004-11-03 | 2006-06-30 | 재단법인서울대학교산학협력재단 | 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법 |
KR100754667B1 (ko) * | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
JP2010106019A (ja) | 2008-10-02 | 2010-05-13 | Kanazawa Univ | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤 |
AR081755A1 (es) * | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
AR080993A1 (es) * | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
KR20120002129A (ko) * | 2010-06-30 | 2012-01-05 | 한미홀딩스 주식회사 | 면역글로불린 단편을 이용한 제7인자(Factor Ⅶa)약물 결합체 |
-
2004
- 2004-11-13 WO PCT/KR2004/002942 patent/WO2005047334A1/en active Application Filing
- 2004-11-13 JP JP2006539396A patent/JP2007531513A/ja active Pending
- 2004-11-13 CN CN2004800017702A patent/CN1723219B/zh active Active
- 2004-11-13 ES ES04800092T patent/ES2426169T3/es active Active
- 2004-11-13 JP JP2006539399A patent/JP5216216B2/ja active Active
- 2004-11-13 ES ES04800090T patent/ES2372495T3/es active Active
- 2004-11-13 WO PCT/KR2004/002944 patent/WO2005047336A1/en active Application Filing
- 2004-11-13 EP EP04800092.1A patent/EP1682584B1/en active Active
- 2004-11-13 PT PT100091297T patent/PT2256134E/pt unknown
- 2004-11-13 CA CA2512657A patent/CA2512657C/en active Active
- 2004-11-13 WO PCT/KR2004/002945 patent/WO2005047337A1/en active Application Filing
- 2004-11-13 US US10/535,341 patent/US8846874B2/en active Active
- 2004-11-13 AU AU2004282984A patent/AU2004282984B2/en active Active
- 2004-11-13 BR BRPI0406605A patent/BRPI0406605B8/pt active IP Right Grant
- 2004-11-13 KR KR1020040092781A patent/KR100775343B1/ko active Protection Beyond IP Right Term
- 2004-11-13 US US10/535,231 patent/US7736653B2/en active Active
- 2004-11-13 KR KR1020040092782A patent/KR100725315B1/ko active Protection Beyond IP Right Term
- 2004-11-13 KR KR1020040092780A patent/KR20050047030A/ko not_active Application Discontinuation
- 2004-11-13 AT AT04800089T patent/ATE555133T1/de active
- 2004-11-13 MX MXPA05007210A patent/MXPA05007210A/es active IP Right Grant
- 2004-11-13 CN CN201810616347.7A patent/CN108743967B/zh active Active
- 2004-11-13 AT AT04800091T patent/ATE540980T1/de active
- 2004-11-13 CN CNA2004800017755A patent/CN1723220A/zh active Pending
- 2004-11-13 ES ES04800091T patent/ES2378167T3/es active Active
- 2004-11-13 EP EP04800091A patent/EP1682583B1/en active Active
- 2004-11-13 ES ES04800089T patent/ES2383300T3/es active Active
- 2004-11-13 WO PCT/KR2004/002943 patent/WO2005047335A1/en active Application Filing
- 2004-11-13 PT PT100063262T patent/PT2239273E/pt unknown
- 2004-11-13 AU AU2004282985A patent/AU2004282985B8/en active Active
- 2004-11-13 RU RU2005120239/13A patent/RU2352583C2/ru active
- 2004-11-13 US US10/535,312 patent/US8029789B2/en active Active
- 2004-11-13 AT AT04800090T patent/ATE522548T1/de not_active IP Right Cessation
- 2004-11-13 ES ES10006326.2T patent/ES2438098T3/es active Active
- 2004-11-13 CN CN201210190634.9A patent/CN103212084B/zh active Active
- 2004-11-13 EP EP04800090A patent/EP1682582B1/en active Active
- 2004-11-13 DK DK04800091.3T patent/DK1682583T3/da active
- 2004-11-13 US US10/535,232 patent/US7737260B2/en active Active
- 2004-11-13 MX MXPA05007211A patent/MXPA05007211A/es active IP Right Grant
- 2004-11-13 JP JP2006539398A patent/JP4870569B2/ja active Active
- 2004-11-13 PL PL10006326T patent/PL2239273T3/pl unknown
- 2004-11-13 EP EP10006326.2A patent/EP2239273B1/en active Active
- 2004-11-13 EP EP04800089A patent/EP1682581B1/en active Active
- 2004-11-13 JP JP2006539397A patent/JP4762904B2/ja active Active
- 2004-11-13 PT PT04800091T patent/PT1682583E/pt unknown
- 2004-11-13 CA CA2512933A patent/CA2512933C/en not_active Expired - Fee Related
- 2004-11-13 PL PL10009129T patent/PL2256134T3/pl unknown
- 2004-11-13 RU RU2005120240/13A patent/RU2356909C2/ru active
- 2004-11-13 ES ES10009129.7T patent/ES2454666T3/es active Active
- 2004-11-13 EP EP10009129.7A patent/EP2256134B1/en active Active
- 2004-11-13 DK DK10009129.7T patent/DK2256134T3/en active
- 2004-11-13 KR KR1020040092783A patent/KR100725314B1/ko active IP Right Grant
- 2004-11-13 DK DK10006326.2T patent/DK2239273T3/da active
- 2004-11-13 BR BR0406606-5A patent/BRPI0406606A/pt not_active Application Discontinuation
-
2006
- 2006-04-24 KR KR1020060036697A patent/KR20060054252A/ko active Search and Examination
-
2007
- 2007-05-03 US US11/744,162 patent/US20080085862A1/en not_active Abandoned
- 2007-05-10 US US11/747,153 patent/US20080124347A1/en not_active Abandoned
-
2010
- 2010-04-09 US US12/757,635 patent/US20100255014A1/en not_active Abandoned
-
2011
- 2011-04-13 HK HK11103711.9A patent/HK1149570A1/xx unknown
- 2011-04-15 US US13/087,593 patent/US8822650B2/en active Active
- 2011-05-06 HK HK11104515.5A patent/HK1150612A1/xx unknown
- 2011-09-15 JP JP2011202199A patent/JP5425150B2/ja not_active Expired - Fee Related
- 2011-09-26 JP JP2011209594A patent/JP2011256211A/ja not_active Abandoned
-
2012
- 2012-07-26 JP JP2012166208A patent/JP2012224635A/ja not_active Withdrawn
-
2013
- 2013-03-12 US US13/796,135 patent/US10071166B2/en active Active
-
2014
- 2014-07-09 US US14/327,064 patent/US10272159B2/en active Active
- 2014-07-09 US US14/327,120 patent/US9750820B2/en active Active
-
2018
- 2018-07-20 US US16/041,263 patent/US20180326083A1/en active Pending
-
2019
- 2019-03-12 US US16/351,338 patent/US11058776B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007536211A5 (ja) | ||
JP2007537992A5 (ja) | ||
RU2005120240A (ru) | Белковый комплекс, полученный с использованием фрагмента иммуноглобулина, и способ получения такого комплекса | |
RU2312868C2 (ru) | Физиологически активный полипептидный конъюгат, обладающий пролонгированным периодом полувыведения in vivo | |
JP6976400B2 (ja) | 受容体媒介クリアランスが減少した、生理活性ポリペプチド単量体と免疫グロブリンFc断片との結合体及びその製造方法 | |
RU2011102446A (ru) | Полипептидный комплекс, содержащий непептидильный полимер, обладающий тремя функциональными концами | |
TWI693236B (zh) | 保留免疫球蛋白Fc片段對FcRn之結合親和力之免疫球蛋白Fc接合物 | |
RU2014138621A (ru) | Улучшенный способ получения комплекса физиологически активного полипептида | |
JP2020535199A5 (ja) | ||
NZ716251B2 (en) | Conjugate of biologically active polypeptide monomer and immunoglobulin fc fragment with reduced receptor-mediated clearance, and the method for preparing the same |